FDA Approves First US Freeze-Dried Plasma for Emergency Care

The U.S. Food and Drug Administration licensed Ezplaz Freeze Dried Plasma, marking the first time a freeze-dried plasma product has been approved for use in the United States. Developed by Vascular Solutions, LLC, a subsidiary of Teleflex, the product gives emergency medical teams a plasma transfusion option that can be stored at room temperature and prepared in about two and a half minutes, solving critical logistical hurdles for patients in remote settings or combat zones.

Plasma is the liquid portion of blood, and it carries essential proteins and clotting factors that help the human body stop bleeding. Patients frequently require plasma transfusions when severe injuries or illnesses deplete multiple clotting factors at once. Conventional fresh frozen plasma preserves those proteins, but it requires strict freezer storage and dedicated thawing equipment. According to federal reports, those requirements make conventional plasma difficult to transport and administer in ambulances, disaster zones, rural communities, or battlefields far from traditional hospital infrastructure.

Logistical Advancements and Kit Contents

Ezplaz addresses storage barriers by using a freeze-dried, or lyophilized, manufacturing process derived from a single unit of fresh frozen plasma collected from FDA-licensed blood establishments. According to regulatory assessments, the dry product remains stable for 12 months when stored at temperatures between 2 and 25 degrees Celsius, matching a range of 36 to 77 degrees Fahrenheit, and withstands temperature fluctuations.

Unlike traditional products housed in glass bottles, Ezplaz is packaged in a flexible plastic bag to reduce the risk of breakage during transport and handling. Each self-contained kit includes one unit of freeze-dried plasma sealed in an outer foil pouch, a 250-milliliter bag of sterile water for injection, a sterile fluid transfer set, and a sterile blood transfusion set. When medical personnel need to administer the treatment, they inject the sterile water into the plasma bag, reconstituting the product in roughly two and a half minutes.

Blood Type Compatibility and Clinical Indications

Blood group compatibility remains a persistent challenge in emergency medicine. To mitigate the risk of adverse reactions when treating patients before their blood type can be determined, Ezplaz is available in Group AB and Group A with low-titer anti-B blood types, according to the FDA.

The FDA licensed Ezplaz for transfusion in adult patients who need plasma when other conventional plasma products are unavailable. Indications include treating bleeding patients, individuals undergoing massive transfusions, and certain patients taking the blood thinner warfarin who experience bleeding and require urgent reversal of the drug’s effects. Karim Mikhail, acting director of the Center for Biologics Evaluation and Research at the FDA, stated that the licensure addresses an unmet medical need for military personnel and others far from hospital infrastructure.

Patients experiencing life-threatening bleeding in combat zones, disasters, rural settings, or other austere environments may now have faster access to plasma when conventional frozen plasma is unavailable.

These include allergic reactions, transfusion-related lung injury, circulatory overload, and reactions triggered by incompatible blood types. The product is not recommended for individuals with a history of hypersensitivity to plasma products or those with immunoglobulin A deficiency. Regulatory assessments also identified thromboembolic events, where a blood clot blocks a vessel, as an incompletely characterized risk. Consequently, the FDA requires a post-approval study to monitor this specific risk in patients who receive the product. Clinical evidence reviewed prior to approval included an early safety study involving 24 healthy adults, which reported no deaths, serious adverse events, or treatment-related adverse events. The licensure stems from a collaboration authorized under Public Law 115-92, enacted in December 2017, which established a partnership between the DoD and the FDA to expedite the development and review of products for serious conditions facing American military personnel. Anne Eder, director of the Office of Blood Research and Review at CBER, noted that the approval demonstrates how innovation and scientific review can expand treatment options while maintaining federal standards for safety, purity, and potency.